SCREENING PROGRAM. (a) NeoGenesis will apply its ALIS method to screen the NeoMorph Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. With respect to each Target delivered by OGS, NeoGenesis shall initiate its screening obligations as more particularly set out in the Program within [*] following the date of receipt of such Target and complete such screening obligations within [*] following the date it commences its screening obligations with respect to such Target, unless the parties agree in writing to extend the period for performance and except as otherwise provided in Section 2.1(a)(ii) (such period, the SCREENING PERIOD). (b) Notwithstanding any provision of this Agreement to the contrary, it is understood and agreed that while NeoGenesis will attempt to complete the Program within thirty six (36) months following the Effective Date, in the event and to the extent that NeoGenesis has not completed the Program with respect to any Target(s) disclosed by OGS within thirty three (33) months following the Program Commencement Date (or thereafter with respect to Targets that are excluded by NeoGenesis as contemplated by Section 2.1(a)) NeoGenesis will continue to perform the Program during the period following the expiration of thirty six (36) months following the Effective Date until NeoGenesis completes the Program for each Target submitted in accordance with Section 2.1(a) and NeoGenesis shall not ▇▇▇▇ OGS any additional fees with respect to the work required to complete the Program with respect to such Targets following the expiration of such thirty six (36) month period; PROVIDED, OGS has paid all fees required under Section 4.2 and PROVIDED FURTHER that NeoGenesis may ▇▇▇▇ OGS for any additional fees due NeoGenesis in respect of "additional" work as contemplated by ATTACHMENT A (Items 6-7).
Appears in 1 contract
Sources: Confidential Treatment Agreement (Neogenesis Pharmaceuticals Inc)
SCREENING PROGRAM. (a) NeoGenesis will apply its ALIS method to screen the NeoMorph Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. With respect to each Target delivered by OGS, NeoGenesis shall initiate its screening obligations as more particularly set out in the Program within [*] following the date of receipt of such Target and complete such screening obligations within [*] following the date it commences its screening obligations with respect to such Target, unless the parties agree in writing to extend the period for performance and except as otherwise provided in Section 2.1(a)(ii) (such period, the SCREENING PERIOD).
(b) Notwithstanding any provision of this Agreement to the contrary, it is understood and agreed that while NeoGenesis will attempt to complete the Program within thirty six (36) months following the Effective Date, in the event and to the extent that NeoGenesis has not completed the Program with respect to any Target(s) disclosed by OGS within thirty three (33) months following the Program Commencement Date (or thereafter with respect to Targets that are excluded by NeoGenesis as contemplated by Section 2.1(a)) NeoGenesis will continue to perform the Program during the period following the expiration of thirty six (36) months following the Effective Date until NeoGenesis completes the Program for each Target submitted in accordance with Section 2.1(a) and NeoGenesis shall not ▇▇▇▇ OGS any additional fees with respect to the work required to complete the Program with respect to such Targets following the expiration of such thirty six (36) month period; PROVIDED, OGS has paid all fees required under Section 4.2 and PROVIDED provided FURTHER that NeoGenesis may ▇▇▇▇ OGS for any additional fees due NeoGenesis in respect of "additional" work as contemplated by ATTACHMENT A (Items 6-7).
Appears in 1 contract
Sources: Screening and Analysis Services Agreement (Neogenesis Pharmaceuticals Inc)